We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+14.9%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$272M
AUM Growth
+$12.6M
Cap. Flow
-$13.6M
Cap. Flow %
-4.98%
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$4.13M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$2.18M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.07M
4
CLF icon
Cleveland-Cliffs
CLF
+$1.9M
5
FERG icon
Ferguson
FERG
+$1.82M

Top Sells

Rank Stock Value
1
ACI icon
Albertsons Companies
ACI
+$4.15M
2
SWTX
SpringWorks Therapeutics
SWTX
+$3.03M
3
GEV icon
GE Vernova
GEV
+$2.41M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$2.1M
5
BHC icon
Bausch Health
BHC
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 37.62%
2 Technology 22.09%
3 Industrials 8.52%
4 Financials 6.08%
5 Consumer Discretionary 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
126
Ascendis Pharma A/S
ASND
$16.8B
$513K 0.19%
2,974
-3,098
-51% -$505K
TCOM icon
127
Trip.com Group
TCOM
$29.7B
$496K 0.18%
8,456
-4,000
-32% -$240K
CATX icon
128
Perspective Therapeutics
CATX
$342M
$476K 0.17%
138,350
– –
TARS icon
129
Tarsus Pharmaceuticals
TARS
$2.97B
$473K 0.17%
+11,680
New +$526K
ETNB
130
DELISTED
89bio
ETNB
$468K 0.17%
+47,633
New +$394K
NOK icon
131
Nokia
NOK
$51B
$433K 0.16%
+83,500
New +$430K
ALC icon
132
Alcon
ALC
$35.9B
$430K 0.16%
+6,123
New +$549K
BABA icon
133
Alibaba
BABA
$317B
$426K 0.16%
3,757
-3,700
-50% -$438K
PHVS icon
134
Pharvaris
PHVS
$2.43B
$418K 0.15%
23,739
+971
+4% +$15.6K
ABVX
135
Abivax
ABVX
$11.1B
$391K 0.14%
51,156
+2,092
+4% +$13.6K
IRON icon
136
Disc Medicine
IRON
$3.01B
$357K 0.13%
6,733
+275
+4% +$12.9K
NAMS icon
137
NewAmsterdam Pharma
NAMS
$3.34B
$349K 0.13%
+19,274
New +$352K
DNTH icon
138
Dianthus Therapeutics
DNTH
$6.25B
$295K 0.11%
15,861
-15,526
-49% -$291K
CGON icon
139
CG Oncology
CGON
$6.79B
$269K 0.1%
10,328
-11,977
-54% -$289K
XNCR icon
140
Xencor
XNCR
$1.6B
$262K 0.1%
33,304
+1,362
+4% +$12.2K
DYN icon
141
Dyne Therapeutics
DYN
$4.95B
$251K 0.09%
26,324
-52,096
-66% -$574K
CGEM icon
142
Cullinan Oncology
CGEM
$1.18B
$240K 0.09%
31,893
– –
TYRA icon
143
Tyra Biosciences
TYRA
$1.57B
$239K 0.09%
24,962
+1,021
+4% +$9.7K
WVE icon
144
Wave Life Sciences
WVE
$1.2B
$234K 0.09%
35,958
-17,416
-33% -$115K
GERN icon
145
Geron
GERN
$949M
$187K 0.07%
132,711
+5,427
+4% +$7.69K
TAL icon
146
TAL Education Group
TAL
$6.93B
$185K 0.07%
+18,100
New +$187K
AAL icon
147
American Airlines Group
AAL
$9.93B
– –
-126,100
Closed -$1.33M
ACI icon
148
Albertsons Companies
ACI
$5.89B
– –
-188,753
Closed -$4.15M
ACN icon
149
Accenture
ACN
$109B
– –
-1,800
Closed -$562K
ARVN icon
150
Arvinas
ARVN
$588M
– –
-41,271
Closed -$290K
4 5
6
7 8

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2025 Portfolio in Review

As of Q2 2025, HighVista Strategies held 177 positions worth $272M, up 4.9% from $260M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $13.6M in Q2 2025, closing 31 positions and reducing 55 holdings. Its most notable exit was Albertsons Companies, an estimated $4.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Mineralys Therapeutics worth $2.03M.

  • HighVista Strategies's largest Q2 2025 buy was Mineralys Therapeutics: 150,138 shares worth $2.03M.
  • HighVista Strategies added most to Viridian Therapeutics in Q2 2025, an estimated $4.13M increase.
  • HighVista Strategies's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $2.41M.
  • HighVista Strategies fully exited Albertsons Companies in Q2 2025, selling an estimated $4.15M.
  • HighVista Strategies's ten largest holdings make up 27% of its $272M portfolio in Q2 2025.
  • HighVista Strategies opened 29 new positions and closed 31 in Q2 2025.
  • HighVista Strategies's portfolio value rose 4.9% quarter-over-quarter to $272M.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.